BETAINE

Post-LOE

betaine anhydrous

ANDAORALFOR SOLUTION

Approved

Jan 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

BETAINE (betaine anhydrous) is methylating activity [moa]. Approved for homocystinuria to decrease elevated homocysteine blood concentrations in pediatric. First approved in 2022.

Drug data last refreshed 4h ago

Mechanism of Action

Methylating Activity

Pharmacologic Class:

Methylating Agent

Indications (1)

homocystinuria to decrease elevated homocysteine blood concentrations in pediatric

External Resources

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.